Heterogeneity underlies the emergence of EGFRT790wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor

Cancer Discovery

Volumn 5, Issue 7, 2015, Pages 713-723

  Piotrowska, Zofia ^a,d   Niederst, Matthew J ^a,d   Karlovich, Chris A ^b   Wakelee, Heather A ^c   Neal, Joel W ^c   Mino Kenudson, Mari ^a,d   Fulton, Linnea ^a   Hata, Aaron N ^a,d   Lockerman, Elizabeth L ^a   Kalsy, Anuj ^a   Digumarthy, Subba ^a,d   Muzikansky, Alona ^a,d   Raponi, Mitch ^b   Garcia, Angel R ^a   Mulvey, Hillary E ^a   Parks, Melissa K ^a   DiCecca, Richard H ^a   Dias Santagata, Dora ^a,d   Iafrate, A John ^a,d   Shaw, Alice T ^a,d   Allen, Andrew R ^b   Engelman, Jeffrey A ^a,d   Sequist, Lecia V ^a,d   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Clovis Oncology Inc   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; ROCILETINIB; ACRYLAMIDE DERIVATIVE; DNA; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SMALL CELL LUNG CANCER; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR GROWTH; WILD TYPE; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG RESISTANCE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MUTATION; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ACRYLAMIDES; CELL LINE, TUMOR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; LUNG NEOPLASMS; MUTATION; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA;

EID: 84937414146     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0399     Document Type: Article

References (28)

1. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and fi nal overall survival results from a phase III, randomized, open-label, fi rst-line study of gefi tinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29: 2866-74.
2. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 2015; 16: 141-51.
3. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75-26.
4. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240-7.
5. Sequist LV, Gerber DE, Fidias P, Shaw AT, Temel JS, Heist R S, et al. Acquired resistance to afatinib in EGFR-mutant lung cancer. Int J Radiat Oncol Biol Phys 2014; 90: S43–S4.
6. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31: 3987-96.
7. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
8. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defi nes lung cancer evolution. Science 2014; 346: 251-6.
9. Zhang J, Fujimoto J, Wedge DC, Song X, Seth S, Chow CW, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 2014; 346: 256–9.
10. Piotrowska Z, Niederst MJ, Mino-Kenudson M, Morales-Oyarvide V, Fulton L, Lockerman E, et al. Variation in mechanisms of acquired resistance among EGFR-mutant NSCLC patients with more than 1 post-resistant biopsy: metastatic non–small cell lung cancer. Int J Radiat Oncol Biol Phys 2014; 90: S6-S7.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplifi cation leads to gefi tinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
12. Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, et al. Reciprocal and complementary role of MET amplifi cation and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 5489-98.
13. Sequist LV, Soria J-C, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, et al. Rociletinib in EGFR mutant non small-cell lung cancer. N Engl J Med 2015; 372: 1700-8.
14. Janne P, Yang J-H, Kim D-W. AZD9291 in EGFR inhibitor-resistant non–small cell lung cancer. N Engl J Med 2015; 372: 1689-99.
15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
16. Niederst MJ, Engelman JA. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci Signal 2013; 6: 6.
17. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun 2015; 6: 6377.
18. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, et al. Amplifi cation of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29: 2346-56.
19. Govindan R, Ding L, Griffi th M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non–small cell lung cancer in smokers and never-smokers. Cell 2012; 150: 1121-34.
20. Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantifi cation of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005; 102: 16368-73.
21. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
22. Avizienyte E, Ward RA, Garner AP. Comparison of the EGFR resistance mutation profi les generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 2008; 415: 197-206.
23. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010; 2: 146-58.
24. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med 2014; 20: 1479-84.
25. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profi ling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-31.
26. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, et al. First-line gefi tinib in patients with advanced non–small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-9.
27. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, Lockerman EL, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014; 346: 1480-6.
28. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012; 180: 599-607.